138 related articles for article (PubMed ID: 2661733)
1. Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.
Paciucci PA; Holland JF; Glidewell O; Odchimar R
J Clin Oncol; 1989 Jul; 7(7):869-78. PubMed ID: 2661733
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2.
Wang JC; Walle A; Novogrodsky A; Suthanthiran M; Silver RT; Bander NH; Rubin AL; Stenzel KH
J Clin Oncol; 1989 Dec; 7(12):1885-91. PubMed ID: 2555451
[TBL] [Abstract][Full Text] [Related]
3. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
[TBL] [Abstract][Full Text] [Related]
4. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
5. Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Levitt D; Fefer A
J Clin Oncol; 1988 Apr; 6(4):669-78. PubMed ID: 3258631
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with IL2 by constant infusion and weekly doxorubicin.
Paciucci PA; Bekesi JG; Ryder JS; Odchimar R; Chahinian PA; Holland JF
Am J Clin Oncol; 1991 Aug; 14(4):341-8. PubMed ID: 1830717
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.
Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH; Sznol M; Mier J; Sparano J; Fisher RI; Weiss G
J Clin Oncol; 1991 Apr; 9(4):641-8. PubMed ID: 2066760
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
9. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
11. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
Rosenberg SA; Lotze MT; Muul LM; Chang AE; Avis FP; Leitman S; Linehan WM; Robertson CN; Lee RE; Rubin JT
N Engl J Med; 1987 Apr; 316(15):889-97. PubMed ID: 3493432
[TBL] [Abstract][Full Text] [Related]
12. Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.
Thompson JA; Lee DJ; Cox WW; Lindgren CG; Collins C; Neraas KA; Dennin RA; Fefer A
Cancer Res; 1987 Aug; 47(15):4202-7. PubMed ID: 3496957
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2.
Curti BD; Longo DL; Ochoa AC; Conlon KC; Smith JW; Alvord WG; Creekmore SP; Fenton RG; Gause BL; Holmlund J
J Clin Oncol; 1993 Apr; 11(4):652-60. PubMed ID: 8257476
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer.
Curti BD; Ochoa AC; Powers GC; Kopp WC; Alvord WG; Janik JE; Gause BL; Dunn B; Kopreski MS; Fenton R; Zea A; Dansky-Ullmann C; Strobl S; Harvey L; Nelson E; Sznol M; Longo DL
J Clin Oncol; 1998 Aug; 16(8):2752-60. PubMed ID: 9704728
[TBL] [Abstract][Full Text] [Related]
15. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.
Osenga KL; Hank JA; Albertini MR; Gan J; Sternberg AG; Eickhoff J; Seeger RC; Matthay KK; Reynolds CP; Twist C; Krailo M; Adamson PC; Reisfeld RA; Gillies SD; Sondel PM;
Clin Cancer Res; 2006 Mar; 12(6):1750-9. PubMed ID: 16551859
[TBL] [Abstract][Full Text] [Related]
17. Influence of schedule of interleukin 2 administration on therapy with interleukin 2 and lymphokine activated killer cells.
Thompson JA; Lee DJ; Lindgren CG; Benz LA; Collins C; Shuman WP; Levitt D; Fefer A
Cancer Res; 1989 Jan; 49(1):235-40. PubMed ID: 2783243
[TBL] [Abstract][Full Text] [Related]
18. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
[TBL] [Abstract][Full Text] [Related]
19. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
